Covariate | Estimate | SE | 95% CI | p-value | |
---|---|---|---|---|---|
Lower | Upper | ||||
Intercept | 3.948 | 0.0617 | 3.8270 | 4.0689 | < 0.0001*** |
Age | 0.043 | 0.0128 | 0.0179 | 0.0681 | 0.0007*** |
Sex(ref = Male) |  |  |  |  |  |
Female | 0.0725 | 0.0561 | -0.0374 | 0.1824 | 0.1962 |
Residence (ref = Rural) |  |  |  |  |  |
Urban | 0.0259 | 0.0102 | 0.0059 | 0.0458 | 0.0120* |
FHHTN (No) | Â | Â | Â | Â | Â |
Yes | 0.0637 | 0.0282 | 0.0084 | 0.1189 | 0.0238* |
Stages of HTN (Ref = Pre-stage) |  |  |  |  |  |
Stage I | 0.0859 | 0.0419 | 0.0037 | 0.1680 | 0.0403 |
Stage II | 0.0935 | 0.0306 | 0.0335 | 0.1534 | 0.0022 |
DM (ref = No) |  |  |  |  |  |
Yes | 0.0268 | 0.0046 | 0.0177 | 0.0358 | < 0.0001*** |
CKD (ref = No) |  |  |  |  |  |
Yes | 0.0457 | 0.0013 | 0.0431 | 0.0482 | < 0.0001*** |
TB (ref = No) |  |  |  |  |  |
Yes | 0.0164 | 0.0114 | -0.0059 | 0.0387 | 0.1502 |
Smoking (ref = No) |  |  |  |  |  |
Yes | 0.0682 | 0.0098 | 0.0489 | 0.0874 | < 0.0001*** |
Treatment type (ref = Others) |  |  |  |  |  |
Enalapril | -0.0139 | 0.0105 | -0.0345 | 0.0067 | 0.1856 |
Nifedipine | -0.0354 | 0.0183 | -0.0713 | 0.0005 | 0.0531 |
Enalapril + Nifedipine | -0.0879 | 0.0392 | -0.1647 | -0.011 | 0.0249*** |
Follow-up time | -0.0581 | 0.0059 | -0.0697 | -0.046 | < 0.0001*** |
Random effects | SD | Â | |||
Intercept (\(\:{b}_{0i}\)) | 0.2171 | ||||
Visit time (\(\:{b}_{1i}\)) | 0.0177 | ||||
Corr\(\:\left({b}_{0i},{b}_{1i}\right)\) | -0.488 | ||||
Residual (\(\:{\epsilon\:}_{i}\)) | 0.2236 |